Next Article in Journal
Characterization of Constituents and Anthelmintic Properties of Hagenia abyssinica
Previous Article in Journal
Stability-Indicating Liquid Chromatographic Method for the Quantification of the New Antipsychotic Agent Asenapine in Bulk and in Pharmaceutical Formulation
Article Menu

Article Versions

Export Article

Open AccessArticle
Sci. Pharm. 2012, 80(2), 419-432; doi:10.3797/scipharm.1111-18

Randomized, Crossover and Single-Dose Bioquivalence Study of Two Oral Desogestrel Formulations (Film-Coated Tablets of 75 μg) in Healthy Female Volunteers

1
Clinical Trials Unit-LEIA Foundation, T.D.C. (nowadays, Tecnalia Research & Innovation)-Hospital Txagorritxu, José Atxotegui s/n, 01009, Vitoria, Spain
2
Kymos Pharma Services, S.L., Baldiri i Reixac, 10-12, 08028, Barcelona, Spain
*
Author to whom correspondence should be addressed.
Received: 27 November 2011 / Accepted: 1 March 2012 / Published: 1 March 2012
Download PDF [146 KB, uploaded 29 September 2016]

Abstract

Despite the increase in the substitution of branded medicinal product with generic drugs, this is a controversial issue for some pharmacological groups (such as contraceptives).
The aim of the present clinical trial was to assess the bioequivalence and tolerability of two oral formulations of desogestrel.
Thirty-three healthy female volunteers participated in this randomized and two-way crossover study. During two separate experimental periods, with at least four weeks of washout period, women received a single oral dose of 75 μg of desogestrel from each of the formulations (test formulation and reference formulation). Desogestrel bioavailability was determined by the measurement of 3-ketodesogestrel plasma concentration.
Pharmacokinetic parameters were comparable and the 90% CI for the ratio of Cmax (96.14–114.53%) and AUC0–t (105.73–123.83%) values for the test and reference formulations fell within the established regulatory interval (80–125%). Both formulations were also comparable in terms of tolerability.
From the results of this study it can be concluded that test formulation (desogestrel 75 μg, Cyndea PHARMA S.L.) is bioequivalent to the reference formulation (Cerazet® 75 μg, Organon Española S.A.).
Keywords: Desogestrel; 3-Ketodesogestrel; Low-dose oral contraceptives; Progestogen-only pills; Bioequivalence; Adverse events Desogestrel; 3-Ketodesogestrel; Low-dose oral contraceptives; Progestogen-only pills; Bioequivalence; Adverse events
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

PENA, M.Á.; SANZ, E.; FRANCISCO, S.; ALONSO, A.; ABAJO, Z.; FELIPE, I.; PASCUAL, J.; TOST, D.; BAILAC, S. Randomized, Crossover and Single-Dose Bioquivalence Study of Two Oral Desogestrel Formulations (Film-Coated Tablets of 75 μg) in Healthy Female Volunteers. Sci. Pharm. 2012, 80, 419-432.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top